Help Improve rehabilitation services by taking this survey
Carers’ wellbeing, confidence and health are at the heart of the new National Carers Strategy. For carers in Ireland, this means recognition and acknowledgement of their role as key care partners.
For a number of years we have mentioned the possibility of a new drug called Alemtuzumab being a potential new treatment for people with MS. On 12 June 2012 the makers, Genzyme, announced that the company has made an official application to the Food and Drugs Administration (FDA) in the US and the European Medicines Agency (EMA).
In an article in today's Health Supplement, Professor Orla Hardiman, Consultant Neurologist and world leading researcher into motor neurone disease praised the role of the NAI as a "pivotal force for improving neurological care services in Ireland".
Fingolimod, under the trade name Gilenya, the first oral drug therapy for the treatment of MS, is now available under the direction of a neurologist. Gilenya is licensed as a second line therapy, making it suitable for people that have failed on conventional first line therapies or those individuals with highly active MS.
The MS Ireland blog is your space to talk about the things that matter to you. It's an opportunity to come together with a community of like-minded people and share your stories, advice and tips.
Politicians from all parties are being encouraged by carers to sign a petition supporting the swift publication of the long awaited National Carers Strategy and for a timeframe for its implementation.
Launch of the findings of a national survey of neurological carers as part of events to mark National Carers Week 2012